B-Cancer	0	6	Tumour	Tumour	NN	B-NP
O	7	19	angiogenesis	angiogenesis	NN	I-NP
O	19	20	:	:	:	O
O	21	24	its	its	PRP$	B-NP
O	25	34	mechanism	mechanism	NN	I-NP
O	35	38	and	and	CC	I-NP
O	39	50	therapeutic	therapeutic	JJ	I-NP
O	51	63	implications	implication	NNS	I-NP
O	64	66	in	in	IN	B-PP
B-Cancer	67	76	malignant	malignant	JJ	B-NP
I-Cancer	77	84	gliomas	glioma	NNS	I-NP
O	84	85	.	.	.	O

O	86	98	Angiogenesis	Angiogenesis	NN	B-NP
O	99	101	is	be	VBZ	B-VP
O	102	103	a	a	DT	B-NP
O	104	107	key	key	JJ	I-NP
O	108	113	event	event	NN	I-NP
O	114	116	in	in	IN	B-PP
O	117	120	the	the	DT	B-NP
O	121	132	progression	progression	NN	I-NP
O	133	135	of	of	IN	B-PP
B-Cancer	136	145	malignant	malignant	JJ	B-NP
I-Cancer	146	153	gliomas	glioma	NNS	I-NP
O	153	154	.	.	.	O

O	155	158	The	The	DT	B-NP
O	159	167	presence	presence	NN	I-NP
O	168	170	of	of	IN	B-PP
B-Tissue	171	184	microvascular	microvascular	JJ	B-NP
O	185	198	proliferation	proliferation	NN	I-NP
O	199	204	leads	lead	VBZ	B-VP
O	205	207	to	to	TO	B-PP
O	208	211	the	the	DT	B-NP
O	212	224	histological	histological	JJ	I-NP
O	225	234	diagnosis	diagnosis	NN	I-NP
O	235	237	of	of	IN	B-PP
B-Cancer	238	250	glioblastoma	glioblastoma	NN	B-NP
I-Cancer	251	261	multiforme	multiforme	NN	I-NP
O	261	262	.	.	.	O

B-Cancer	263	269	Tumour	Tumour	NN	B-NP
O	270	282	angiogenesis	angiogenesis	NN	I-NP
O	283	291	involves	involve	VBZ	B-VP
O	292	300	multiple	multiple	JJ	B-NP
B-Cell	301	309	cellular	cellular	JJ	I-NP
O	310	319	processes	process	NNS	I-NP
O	320	329	including	include	VBG	B-PP
B-Cell	330	341	endothelial	endothelial	JJ	B-NP
I-Cell	342	346	cell	cell	NN	I-NP
O	347	360	proliferation	proliferation	NN	I-NP
O	360	361	,	,	,	O
O	362	371	migration	migration	NN	B-NP
O	371	372	,	,	,	O
O	373	387	reorganisation	reorganisation	NN	B-NP
O	388	390	of	of	IN	B-PP
B-Cellular_component	391	404	extracellular	extracellular	JJ	B-NP
I-Cellular_component	405	411	matrix	matrix	NN	I-NP
O	412	415	and	and	CC	I-NP
B-Tissue	416	420	tube	tube	NN	I-NP
O	421	430	formation	formation	NN	I-NP
O	430	431	.	.	.	O

O	432	437	These	These	DT	B-NP
O	438	447	processes	process	NNS	I-NP
O	448	451	are	be	VBP	B-VP
O	452	461	regulated	regulate	VBN	I-VP
O	462	464	by	by	IN	B-PP
O	465	473	numerous	numerous	JJ	B-NP
O	474	477	pro	pro	AFX	I-NP
O	477	478	-	-	HYPH	I-NP
O	478	488	angiogenic	angiogenic	JJ	I-NP
O	489	492	and	and	CC	I-NP
O	493	497	anti	anti	AFX	I-NP
O	497	498	-	-	HYPH	I-NP
O	498	508	angiogenic	angiogenic	JJ	I-NP
O	509	515	growth	growth	NN	I-NP
O	516	523	factors	factor	NNS	I-NP
O	523	524	.	.	.	O

O	525	537	Angiogenesis	Angiogenesis	NN	B-NP
O	538	548	inhibitors	inhibitor	NNS	I-NP
O	549	553	have	have	VBP	B-VP
O	554	558	been	be	VBN	I-VP
O	559	568	developed	develop	VBN	I-VP
O	569	571	to	to	TO	I-VP
O	572	581	interrupt	interrupt	VB	I-VP
O	582	585	the	the	DT	B-NP
O	586	596	angiogenic	angiogenic	JJ	I-NP
O	597	604	process	process	NN	I-NP
O	605	607	at	at	IN	B-PP
O	608	611	the	the	DT	B-NP
O	612	618	growth	growth	NN	I-NP
O	619	625	factor	factor	NN	I-NP
O	625	626	,	,	,	O
O	627	635	receptor	receptor	NN	B-NP
O	636	644	tyrosine	tyrosine	NN	I-NP
O	645	651	kinase	kinase	NN	I-NP
O	652	655	and	and	CC	O
B-Immaterial_anatomical_entity	656	669	intracellular	intracellular	JJ	B-NP
O	670	676	kinase	kinase	NN	I-NP
O	677	683	levels	level	NNS	I-NP
O	683	684	.	.	.	O

O	685	690	Other	Other	JJ	B-NP
O	691	695	anti	anti	AFX	I-NP
O	695	696	-	-	HYPH	I-NP
O	696	706	angiogenic	angiogenic	JJ	I-NP
O	707	716	therapies	therapy	NNS	I-NP
O	717	722	alter	alter	VBP	B-VP
O	723	726	the	the	DT	B-NP
O	727	733	immune	immune	JJ	I-NP
O	734	742	response	response	NN	I-NP
O	743	746	and	and	CC	O
O	747	758	endogeneous	endogeneous	JJ	B-NP
O	759	771	angiogenesis	angiogenesis	NN	I-NP
O	772	781	inhibitor	inhibitor	NN	I-NP
O	782	788	levels	level	NNS	I-NP
O	788	789	.	.	.	O

O	790	794	Most	Most	JJS	B-NP
O	795	799	anti	anti	AFX	I-NP
O	799	800	-	-	HYPH	I-NP
O	800	810	angiogenic	angiogenic	JJ	I-NP
O	811	820	therapies	therapy	NNS	I-NP
O	821	824	for	for	IN	B-PP
B-Cancer	825	834	malignant	malignant	JJ	B-NP
I-Cancer	835	842	gliomas	glioma	NNS	I-NP
O	843	846	are	be	VBP	B-VP
O	847	849	in	in	IN	B-PP
O	850	855	Phase	Phase	NN	B-NP
O	856	857	I	I	CD	I-NP
O	857	858	/	/	SYM	B-NP
O	858	860	II	II	CD	I-NP
O	861	867	trials	trial	NNS	I-NP
O	868	871	and	and	CC	O
O	872	876	only	only	RB	B-NP
O	877	883	modest	modest	JJ	I-NP
O	884	894	efficacies	efficacy	NNS	I-NP
O	895	898	are	be	VBP	B-VP
O	899	907	reported	report	VBN	I-VP
O	908	911	for	for	IN	B-PP
O	912	925	monotherapies	monotherapy	NNS	B-NP
O	925	926	.	.	.	O

O	927	930	The	The	DT	B-NP
O	931	939	greatest	great	JJS	I-NP
O	940	949	potential	potential	NN	I-NP
O	950	953	for	for	IN	B-PP
O	954	966	angiogenesis	angiogenesis	NN	B-NP
O	967	977	inhibitors	inhibitor	NNS	I-NP
O	978	981	may	may	MD	B-VP
O	982	985	lie	lie	VB	I-VP
O	986	988	in	in	IN	B-PP
O	989	994	their	their	PRP$	B-NP
O	995	1002	ability	ability	NN	I-NP
O	1003	1005	to	to	TO	B-VP
O	1006	1013	combine	combine	VB	I-VP
O	1014	1020	safely	safely	RB	B-ADVP
O	1021	1025	with	with	IN	B-PP
O	1026	1038	chemotherapy	chemotherapy	NN	B-NP
O	1039	1042	and	and	CC	I-NP
O	1043	1055	radiotherapy	radiotherapy	NN	I-NP
O	1055	1056	.	.	.	O

